Shares of Prime Medicine ( PRME 13.07%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.

Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...

Prime Medicine (PRME) unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency, AATD, the next program within its ...

Chardan Capital reaffirmed their buy rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research note released on Monday morning,Benzinga reports. The firm currently has a $15.00 target ...

Stock analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Prime Medicine in a ...

Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

The release of positive FiH data for PM359 in CGD could serve as a significant catalyst for Prime Medicine’s stock. Successful results would not only validate the company’s Prime Editing ...

GLUE Monte Rosa Therapeutics, Inc.

specializes in Prime Editing-based therapies and stands at the forefront of genetic medicine innovation. The stock has declined 35% year-to-date, reflecting broader market uncertainty around ...